Skip to main content

Advertisement

SpringerLink
Log in

Predicting skeletal complications in metastatic breast cancer raises challenges

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

The Original Article was published on 24 June 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ (2002) Global, regional estimates of cancer mortality, incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2:37

    Article  PubMed  Google Scholar 

  2. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176

    Article  CAS  PubMed  Google Scholar 

  3. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594

    Article  CAS  PubMed  Google Scholar 

  4. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335(24):1785–1791

    Article  CAS  PubMed  Google Scholar 

  5. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3):846–854

    CAS  PubMed  Google Scholar 

  6. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321

    Article  CAS  PubMed  Google Scholar 

  7. Major PP, Cook RC, Lipton A, Smith MR, Terpos E, Coleman RE (2009) Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 9:272

    Article  PubMed  Google Scholar 

  8. Hirsh H, Simon Tchekmedyian NS, Rosen LS, Zheng M, Hei Y-J (2004) Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 6:170–174

    Article  CAS  PubMed  Google Scholar 

  9. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 pt 2):6243s–6249s

    Article  PubMed  Google Scholar 

  10. Pavlakis N, Schmidt R, Stockler N (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474

  11. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057

    Article  CAS  PubMed  Google Scholar 

  12. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE (2010) Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-0981-1

  13. Mortimer JE, Schulman K, Kohles JD (2007) Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. Clin Breast Cancer 7(9):682–689

    Article  PubMed  Google Scholar 

  14. Mirels H (1989) Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop 249:256–264

    PubMed  Google Scholar 

  15. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 4(7):1765–1772

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Michigan, Ann Arbor, MI, USA

    Catherine Van Poznak

Authors
  1. Catherine Van Poznak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Van Poznak.

Additional information

This is an invited commentary to article doi:10.1007/s10549-010-0981-1.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Poznak, C. Predicting skeletal complications in metastatic breast cancer raises challenges. Breast Cancer Res Treat 123, 781–783 (2010). https://doi.org/10.1007/s10549-010-1104-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1104-8

Keywords

Search

Navigation